T. Rowe Price Investment Management, Inc.

Position in DNLI — Denali Therapeutics Inc.

CIK 1897612 BALTIMORE, MD

Position in DNLI

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$416,122,928

+$252,554,442 QoQ

Shares Held

16,178,963

+89.9% QoQ

Ownership

10.1%

of shares outstanding

% of Portfolio

0.27%

of 13F equity value

Holder Rank

of 290 holders

Holding Since

Sep 2022

12 quarters on record

Voting authority Sole 97% Shared 0% None 3%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. DNLI ranks #9 (3.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$416,122,928	16,178,963	+89.9%	Shares	Sole	2026-08-14
2026-06-30	$416,122,928	16,178,963	—	Shares	Sole	2026-07-08
2026-03-31	$163,568,486	8,519,192	+583.7%	Shares	Sole	2026-05-15
2025-12-31	$20,571,360	1,245,994	-77.9%	Shares	Sole	2026-02-17
2025-09-30	$81,871,992	5,638,567	+73.7%	Shares	Sole	2025-11-14
2025-06-30	$45,424,606	3,246,934	+550.7%	Shares	Sole	2025-08-14
2024-03-31	$10,238,843	498,969	0.0%	Shares	Sole	2024-05-15
2023-12-31	$10,707,874	498,969	-22.9%	Shares	Sole	2024-02-14
2023-09-30	$13,347,878	647,013	0.0%	Shares	Sole	2023-11-14
2023-06-30	$19,093,353	647,013	0.0%	Shares	Sole	2023-08-14
2023-03-31	$14,907,179	647,013	+2.2%	Shares	Sole	2023-05-15
2022-12-31	$17,613,685	633,358	+50.0%	Shares	Sole	2023-02-14
2022-09-30	$12,962,136	422,357	—	Shares	Sole	2022-11-14
No filing history on record for this holder in this stock.